RET and non-small cell lung carcinoma: As an example, in patients with stage IB-IIIA RET fusion-positive NSCLC previously treated with standard therapy, the ongoing phase III LIBRETTO-432 study is evaluating adjuvant selpercatinib versus a placebo [40].